Incidence of and survival following brain metastases among women with inflammatory breast cancer

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2348-2355

  Dawood, S ^a,b   Ueno, N T ^a   Valero, V ^a   Andreopoulou, E ^a   Hsu, L ^a   Lara, J ^a   Woodward, W ^a   Buchholz, T A ^a   Hortobagyi, G N ^a   Cristofanilli, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

Brain metastases; Breast tumor subtypes; Incidence; Inflammatory breast cancer; Risk; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BREAST CANCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 78649465583     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq239     Document Type: Article

References (25)

1. Hance KW, Anderson WF, Devesa SS et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97(13): 966-975.
2. Bozzetti F, Saccozzi R, Lena MD, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol 1981; 18: 355-361.
3. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis 2005-2006; 22: 67-73.
4. Ueno NT, Buzdar AU, Singletary SE et al. Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D Anderson Center. Cancer Chemother Pharmacol 1997; 40(4): 321-329.
5. Cristofanilli M, Valero V, Buzdar AU et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 2007; 110(7): 1436-1444.
6. DiStefano A, Yap HY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44: 1913-1918.
7. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97(12): 2972-2977.
8. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebralmetastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91(4): 639-643.
9. Singletary SE, Allred C, Ashley P et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83: 803-819.
10. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
11. Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004; 101(8): 1760-1766.
12. Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 2006; 45(2): 196-201.
13. Stemmler HJ, Kahlert S, Siekiera W et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15(2): 219-225.
14. Altaha R, Crowell E, Hobbs G et al. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma. Cancer 2005; 103(3): 442-443.
15. Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15(4): 1452-1459.
16. Cristofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res and Treat 2006; (Abstr 1).
17. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastases. Nature 2001; 410: 50-56.
18. Smith MCP, Luker KE, Garbow JR et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612.
19. Cabioglu N, Gong Y, Islam R et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 2007; 18(6): 1021-1029.
20. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
21. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
22. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19(7): 1242-1248.
23. Nam BH, Kim SY, Han HS et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10(1): R20.
24. Svoboda M, Fabian P, Ondrova B et al. Brain metastases in breast cancer: a retrospective cohort study of 187 patients and prognostic markers determination. In San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. (Abstr 6020). 2007.
25. Dawood S, Broglio K, Gong Y et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008; 112(9): 1905-1911.